Key Stats for MIRM Stock
- Price Change for MIRM stock: -15%
- MIRM Share Price as of Feb. 26: $92
- 52-Week High: $109
- MIRM Stock Price Target: $120
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Mirum Pharmaceuticals (MIRM) stock fell 15.1% on February 26, 2026. Shares closed at $92 after the company reported Q4 results and disclosed a share offering. The decline followed news that selling stockholders may offer up to 8.96 million shares.
On the earnings front, Q4 net product sales rose 49.8% to $148.9 million, according to Reuters. The company also reported that 2025 sales increased year over year. However, the equity overhang pressured the stock.
Mirum had previously projected 2026 global net product sales of up to $650 million. Investors appear focused on potential dilution rather than commercial momentum. As a result, shares pulled back sharply from recent highs.
Despite the drop, the stock remains well above its 52-week low of $37. Still, near-term sentiment shifted following the offering announcement.
See analysts’ growth forecasts and price targets for MIRM stock (It’s free!) >>>
What the Market Is Telling Us About MIRM Stock
Mirum Pharmaceuticals is a biotechnology company focused on rare liver diseases. Its lead product, LIVMARLI, is approved for cholestatic pruritus in Alagille syndrome. The company also commercializes Cholbam and Chenodal.
From a balance sheet standpoint, Mirum holds a net cash position. LTM net debt is negative $63.9 million, and net debt to EBITDA is -14.2x. Enterprise value is $5.5 billion versus a $5.6 billion market cap.
The stock’s 5-year beta is 0.50, which indicates lower volatility than many biotech peers. However, secondary offerings can trigger sharp moves. Investors often reassess valuation when supply increases.
Mirum recently completed the acquisition of Bluejay Therapeutics. The company also received Health Canada authorization for LIVMARLI in PFIC and Alagille syndrome earlier this year. Those developments support pipeline expansion.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Mirum Pharmaceuticals, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up MIRM, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track MIRM alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Mirum Pharmaceuticals stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
